Bryan Johnson, the Venmo billionaire, made headlines with Project Blueprint—a series of young-to-old plasma transfusions between himself and his teenage son, conducted under the premise that young blood could slow or reverse aging. The photoshoot, featuring shirtless vials of each other's plasma, was widely mocked as literal vampirism. While some scientists have studied the rejuvenating effects of young blood through heterochronic parabiosis in mice—which showed improvements in muscle regeneration, neurogenesis, and reduced inflammation—human applications remain largely experimental. Johnson's self-experimentation, using assays from companies like Tru Diagnostic at $1,799 annually, lacks scientific rigor and reproducibility. The article argues that such ventures, driven by venture capital thinking, prioritize individual immortality over public health benefits. Instead, the focus should be on understanding the underlying mechanisms of aging through basic science, potentially leading to scalable, affordable therapeutics. Promising clinical trials are already investigating plasma-based treatments for Alzheimer’s and Parkinson’s diseases, highlighting the potential for broader societal impact when research is guided by scientific inquiry rather than personal wealth.

The author critiques the commercialization of longevity research, emphasizing that true progress requires democratizing access to treatments derived from rigorous scientific methods. Johnson's approach, while attention-grabbing, fails to contribute meaningfully to the field compared to peer-reviewed studies aimed at public welfare.

Ultimately, the piece calls for a shift from elitist biohacking to inclusive scientific exploration, advocating for treatments that benefit all rather than just the ultra-wealthy.